{"ATC Code":["V - Various","V06 - General nutrients","V06D - Other nutrients","V06DC - Carbohydrates","V06DC01 - Glucose","B - Blood and blood forming organs","B05 - Blood substitutes and perfusion solutions","B05C - Irrigating solutions","B05CX - Other irrigating solutions","B05CX01 - Glucose","V - Various","V04 - Diagnostic agents","V04C - Other diagnostic agents","V04CA - Tests for diabetes","V04CA02 - Glucose","QV - Various","QV04 - Diagnostic agents","QV04C - Other diagnostic agents","QV04CA - Tests for diabetes","QV04CA02 - Glucose","QB - Blood and blood forming organs","QB05 - Blood substitutes and perfusion solutions","QB05C - Irrigating solutions","QB05CX - Other irrigating solutions","QB05CX01 - Glucose","QV - Various","QV06 - General nutrients","QV06D - Other nutrients","QV06DC - Carbohydrates","QV06DC01 - Glucose","B05CX01"],"Abbreviation":[],"Absorption, Distribution and Excretion":"Polysaccharides can be broken down into smaller units by pancreatic and intestinal glycosidases or intestinal flora. Sodium-dependent glucose transporter SGLT1 and GLUT2 (SLC2A2) play predominant roles in intestinal transport of glucose into the circulation. SGLT1 is located in the apical membrane of the intestinal wall while GLUT2 is located in the basolateral membrane, but it was proposed that GLUT2 can be recruited into the apical membrane after a high luminal glucose bolus allowing bulk absorption of glucose by facilitated diffusion. Oral preparation of glucose reaches the peak concentration within 40 minutes and the intravenous infusions display 100% bioavailability.","Aliases":["Glucose","Glucopyranose","Glc","Blood sugar","Grape sugar","Traubenzucker","Glucosteril","Cartose","anhydrous glucose","Maxim Energy Gel","Glucosum, anhydrous","Staleydex 333","Corn sugar","glucopyranoside","Glucose, α-d-","Cerelose","pur","sol","Glucolin","Goldsugar","Vadex","Staleydex 111","Cerelose 2001","Tabfine 097(HS)","AI3-09328","gluco-hexose","glc","se 25%","Clintec","gel","Gambrosol","Leukotrap","Rapilose","Yourgluco","Dextrose 60%"," energy","Gsf-syrup","Purified Glucose","D Glucose","se 5% in plastic container","Glucose, unspecified","SNFG:Glc","Glucose in linear","Monohydrate, Glucose","LINGTEA","se 10% in plastic container","se 20% in plastic container","se 30% in plastic container","se 40% in plastic container","se 50% in plastic container","se 60% in plastic container","se 70% in plastic container","se 2.5% in plastic container","se 7.7% in plastic container","Blood Collection System","se 38.5% in plastic container","Leukotrap-CP2D Solution","GlyTouCan:G15021LG","Basic Dental Emergency Kit","Dextrose 50%","Leukotrap WB System-CP2D","Deluxe Dental Emergency Kit","IY9XDZ35W2","Nutricel Additive System-CP2D","Chebi:17234","Chebi:17634","Nutricel Additive Solution-CP2D","G15021LG","Anticoagulant Citrate Phosphate Double Dextrose","Epinephrine, Albuterol Sulfate, Nitroglycerin, Diphenhydramine Hydrochloride, Aspirin","200-075-1","218-914-5","807-615-0","50-99-7","5SL0G7R0OK","α-D-Glucopyranose, hydrate","Anhydrous Dextrose","D(+)-Glucose","Glucose, anhydrous","se","se Anhydrous","Dtxcid707720","Dtxsid7022910","Glucopyranoside","Glucose anhydrous","Glucose liquid","Glucose-40","Insta-glucose","NSC 406891","NSC-406891","NSC406891","Sirup","Sugar, grape","2280-44-6","Glcp","54-17-1","Glucopyranose, D-","rel-(3R,4S,5S,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol","CHEBI:4167","(3R,4S,5S,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol","Glucodin","Meritose","Clintose L","CPC hydrate","Roferose ST","Clearsweet 95","Staleydex 95M","Glucopyranose, anhydrous","Liquid glucose","glc-ring","Cartose Cerelose","aGlucopyranose","glucose-ring","Glucose injection","Glucopyranose; Glucopyranose; NSC 287045; Dextrose","Glucose 40","Staleydex 130","Einecs 218-914-5","glucose","Glc-OH","Meritose 200","nchembio867-comp4","starbld0000491","6-(hydroxymethyl)tetrahydropyran-2,3,4,5-tetraol","Purified glucose","Epitope ID:142342","DEXTROSE","Schembl1278","Schembl316109","Schembl674627","GTPL4536","Schembl8725377","Chembl1222250","BDBM34103","Dtxsid501015215","Dtxsid901015217","(3R,4S,5S,6R)-6-(hydroxymethyl)tetrahydropyran-2,3,4,5-tetrol","Mfcd00063684","Glucose 1000 microg/mL in Water","Akos025147374","NSC 287045","Glucose 1000 microg/mL in Methanol","Ncgc00166293-01","BS-48662","G0048","Glucose; Trehalose Dihydrate EP Impurity A","C00031","D00009","F71542","Q37525","Q23905964","N_full/o_full_10000000000000_gs_656","WURCS=2.0/1,1,0/[a2122h-1x_1-5]/1/"],"Biological Half-Life":"The approximate half-life is 14.3 minutes following intravenous infusion. Gut glucose half-life was markedly higher in females (79 ± 2 min) than in males (65 ± 3 min, P \u003c 0.0001) and negatively related to body height (r = -0.481; P \u003c 0.0001).","Boiling Point":"greater than 212 °F at 760 mmHg (USCG, 1999)","CAS":"50-99-7","Chemical Classes":"Biological Agents -\u003e Monosaccharides and Derivatives","ChemicalClasses":[],"Chirality":"racemic","Color/Form":"Colorless crystals or white granular powder","Decomposition":"When heated to decomposition it emits acrid smoke and irritating fumes.","Density":"1.2 at 68 °F (est.) (USCG, 1999) - Denser than water; will sink g/cm\u003csup\u003e3\u003c/sup\u003e","Drug Indication":"Glucose pharmaceutical formulations (oral tablets, injections) are indicated for caloric supply and carbohydrate supplementation in case of nutrient deprivation. It is also used for metabolic disorders such as hypoglycemia.","Drug Warnings":"... the sugar itself may be source of pyrogens, and extreme care must be observed throughout the preparation of dextrose injections to prevent contamination, for conditions are practically ideal for the development of bacteria and, therefore, pyrogens.","Esters":[],"European Community (EC) Number":"200-075-1","Formating":[],"HMDB ID":"HMDB0304632","Health Effects":"High blood glucose (\u003e7 mM) produces the symptoms of frequent urination, increased thirst, and increased hunger. Chronic exposure to high blood glucose (i.e. untreated diabetes) can cause many complications. Acute complications include diabetic ketoacidosis (characterized by nausea, vomiting and abdominal pain, the smell of acetone on the breath) and nonketotic hyperosmolar coma. Serious long-term complications include heart disease, stroke, kidney failure, foot ulcers and damage to the eyes.  The major long-term complications relate to damage to blood vessels. Diabetes doubles the risk of cardiovascular disease and about 75% of deaths in diabetics are due to coronary artery disease. Other \"macrovascular\" diseases are stroke, and peripheral vascular disease. The primary microvascular complications of diabetes include damage to the eyes, kidneys, and nerves. Damage to the eyes, known as diabetic retinopathy, is caused by damage to the blood vessels in the retina of the eye, and can result in gradual vision loss and potentially blindness. Damage to the kidneys, known as diabetic nephropathy, can lead to tissue scarring, urine protein loss, and eventually chronic kidney disease, sometimes requiring dialysis or kidney transplant. Damage to the nerves of the body, known as diabetic neuropathy, is the most common complication of diabetes. The symptoms can include numbness, tingling, pain, and altered pain sensation, which can lead to damage to the skin. Diabetes-related foot problems (such as diabetic foot ulcers) may occur, and can be difficult to treat, occasionally requiring amputation. Gestational diabetes can damage the health of the fetus or mother. Risks to the baby include macrosomia (high birth weight), congenital cardiac and central nervous system anomalies, and skeletal muscle malformations. Increased fetal insulin may inhibit fetal surfactant production and cause respiratory distress syndrome. Hyperbilirubinemia may result from red blood cell destruction.","HeavyAtomCount":12,"Human Drugs":"FDA approved drugs -\u003e Active ingredient","IUPACName":"(3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol","InChI":"InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5-,6?/m1/s1","InChIKey":"WQZGKKKJIJFFOK-GASJEMHNSA-N","Interactions":"Recent studies suggest that meat intake is associated with diabetes-related phenotypes. However, whether the associations of meat intake and glucose and insulin homeostasis are modified by genes related to glucose and insulin is unknown. We investigated the associations of meat intake and the interaction of meat with genotype on fasting glucose and insulin concentrations in Caucasians free of diabetes mellitus. Fourteen studies that are part of the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium participated in the analysis. Data were provided for up to 50,345 participants. Using linear regression within studies and a fixed-effects meta-analysis across studies, we examined 1) the associations of processed meat and unprocessed red meat intake with fasting glucose and insulin concentrations; and 2) the interactions of processed meat and unprocessed red meat with genetic risk score related to fasting glucose or insulin resistance on fasting glucose and insulin concentrations. Processed meat was associated with higher fasting glucose, and unprocessed red meat was associated with both higher fasting glucose and fasting insulin concentrations after adjustment for potential confounders [not including body mass index (BMI)]. For every additional 50-g serving of processed meat per day, fasting glucose was 0.021 mmol/L (95% CI: 0.011, 0.030 mmol/L) higher. Every additional 100-g serving of unprocessed red meat per day was associated with a 0.037-mmol/L (95% CI: 0.023, 0.051-mmol/L) higher fasting glucose concentration and a 0.049-ln-pmol/L (95% CI: 0.035, 0.063-ln-pmol/L) higher fasting insulin concentration. After additional adjustment for BMI, observed associations were attenuated and no longer statistically significant. The association of processed meat and fasting insulin did not reach statistical significance after correction for multiple comparisons. Observed associations were not modified by genetic loci known to influence fasting glucose or insulin resistance. The association of higher fasting glucose and insulin concentrations with meat consumption was not modified by an index of glucose- and insulin-related single-nucleotide polymorphisms.","MeSH Headers":[{"Id":"M0009339","Link":"https://id.nlm.nih.gov/mesh/M0009339.html","Name":"Glucose","Ref":143},{"Id":"M0582743","Link":"https://id.nlm.nih.gov/mesh/M0582743.html","Name":"Anhydrous Dextrose","Ref":145},{"Id":"DescTree","Link":"https://www.nlm.nih.gov/mesh/meshhome.html","Name":"MeSH Tree","Ref":146},{"Id":"PubMed from MeSH","Link":"https://www.nlm.nih.gov/mesh/meshhome.html","Name":null,"Ref":178},{"Id":"M0020928","Link":"https://id.nlm.nih.gov/mesh/M0020928.html","Name":"Sweetening Agents","Ref":179}],"MeSH Pharmacological Classification":[{"Id":"M0020928","Link":"https://id.nlm.nih.gov/mesh/M0020928.html","Name":"Sweetening Agent","Ref":179}],"Mechanism of Action":"Glucose supplies most of the energy to all tissues by generating energy molecules ATP and NADH during a series of metabolism reactions called glycolysis. Glycolysis can be divided into two main phases where the preparatory phase is initiated by the phosphorylation of glucose by hexokinase to form glucose 6-phosphate. The addition of the high-energy phosphate group activates glucose for the subsequent breakdown in later steps of glycolysis and is the rate-limiting step. Products end up as substrates for following reactions, to ultimately convert C6 glucose molecule into two C3 sugar molecules. These products enter the energy-releasing phase where the total of 4ATP and 2NADH molecules are generated per one glucose molecule. The total aerobic metabolism of glucose can produce up to 36 ATP molecules. These energy-producing reactions of glucose are limited to D-glucose as L-glucose cannot be phosphorylated by hexokinase. Glucose can act as precursors to generate other biomolecules such as vitamin C. It plays a role as a signaling molecule to control glucose and energy homeostasis. Glucose can regulate gene transcription, enzyme activity, hormone secretion, and the activity of glucoregulatory neurons. The types, number, and kinetics of glucose transporters expressed depends on the tissues and fine-tunes glucose uptake, metabolism, and signal generation to preserve cellular and whole body metabolic integrity.","Melting Point":"less than 32 °F (USCG, 1999)","Metabolism/Metabolites":"Glucose can undergo aerobic oxidation in conjunction with the synthesis of energy molecules. Glycolysis is the initial stage of glucose metabolism where one glucose molecule is degraded into two molecules of pyruvate via substrate-level phosphorylation. These products are transported to the mitochondria where they are further oxidized into oxygen and carbon dioxide.","MolecularFormula":"C\u003csub\u003e6\u003c/sub\u003eH\u003csub\u003e12\u003c/sub\u003eO\u003csub\u003e6\u003c/sub\u003e","MolecularWeight":"180.16 g/mol","Non-Human Toxicity Values":"LD50 Rat oral 25,800 mg/kg","Odor":"Odorless","Pharmacodynamics":"Blood glucose is an obligatory energy source for humans involved in various cellular activities, and it also acts as a signaling molecule for diverse glucose-sensing molecules and proteins. Glucose undergoes oxidation into carbon dioxide, water, and yields energy molecules in the process of glycolysis and subsequent citric cycle and oxidative phosphorylation. Glucose is readily converted into fat in the body which can be used as a source of energy as required. Under a similar conversion into storage of energy, glucose is stored in the liver and muscles as glycogen. Glucose stores are mobilized in a regulated manner, depending on the tissues' metabolic demands. Oral glucose tablets or injections serve to increase the supply of glucose and oral glucose administration is more effective in stimulating insulin secretion because it stimulates the incretin hormones from the gut, which promotes insulin secretion.","Physical Description":"Watery odorless colorless liquid. Denser than water and soluble in water. Hence sinks in and mixes with water. (USCG, 1999)","PubChemId":5793,"RefChem":"53","RefCount":2,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Glucose","Name":"Glucose","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q23905964","Name":"Glucose","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/DB01914","Name":"Glucose","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/5793","Name":"Glucose","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=50-99-7","Name":"Glucose","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0304632","Name":"Glucose","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C00031","Name":"Glucose","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID501015215","Name":"Glucose","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 5793, Glucose. Accessed February 17, 2026. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/5793\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/5793\u003c/a\u003e"],"SMILES":"C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)O)O)O","SaltData":[],"Salts":[],"Solubility":"Soluble","Stability/Shelf Life":"Stable under recommended storage conditions.","StereoisomerData":[],"StereoisomerType":"enantiomer","Stereoisomers":[],"Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 80.27 67.264\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#ff0d0d\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h81v68H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cpath fill=\"#000\" stroke=\"none\" d=\"m46.573 25.587.35.606 15.624-6.824-2.249-1.299-1.97-1.137z\" class=\"bond\"/\u003e\u003cpath d=\"m46.748 25.89-13.11-7.569M33.638 18.321l-13.291 7.578M20.347 25.899l-.019 15.475M20.328 41.374l13.11 7.569M33.438 48.943l10.036-5.886M46.748 25.89l-.004 11.327M33.438 48.943l.039 11.319\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m20.503 41.677-.35-.606\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m18.742 42.981-.6-1.039M16.981 44.285l-.85-1.473M15.219 45.589l-1.099-1.906M13.458 46.893l-1.349-2.339M11.697 48.198l-1.599-2.773\"/\u003e\u003c/g\u003e\u003cpath fill=\"#000\" stroke=\"none\" d=\"m20.171 26.201.352-.605-9.242-6.898-.837 1.439-.838 1.44z\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m33.288 18.32.7.002\"/\u003e\u003cpath stroke=\"#ff0d0d\" d=\"m33.003 15.779 1.283.004M32.718 13.239l1.867.005M32.433 10.698l2.451.006M32.149 8.157l3.033.008\"/\u003e\u003c/g\u003e\u003cpath d=\"m59.947 18.272 9.914 5.726\" class=\"bond\"/\u003e\u003cpath stroke=\"none\" d=\"M49.002 41.136q0 .756-.256 1.327-.256.566-.756.881t-1.244.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.232.315.5.31.756.875.256.566.256 1.328m-3.863 0q0 .923.387 1.458.393.53 1.22.53.84 0 1.221-.53.386-.535.386-1.458 0-.929-.386-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453\" class=\"atom\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M35.75 64.18q0 .756-.256 1.328-.256.565-.756.881-.5.315-1.244.315-.756 0-1.262-.315-.506-.316-.756-.887-.244-.572-.244-1.334 0-.75.244-1.309.25-.566.756-.882.506-.315 1.274-.315.732 0 1.232.315.5.31.756.876.256.565.256 1.327m-3.863 0q0 .923.387 1.459.393.529 1.22.529.839 0 1.22-.529.387-.536.387-1.459 0-.929-.387-1.452-.381-.524-1.208-.524-.834 0-1.226.524-.393.523-.393 1.452M40.056 66.633h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619z\"/\u003e\u003c/g\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M9.385 48.983q0 .756-.256 1.328-.256.565-.756.881-.5.315-1.245.315-.756 0-1.262-.315-.506-.316-.756-.887-.244-.572-.244-1.334 0-.75.244-1.309.25-.566.756-.882.506-.315 1.274-.315.733 0 1.233.315.5.31.756.876.256.565.256 1.327m-3.864 0q0 .923.387 1.459.393.529 1.22.529.84 0 1.221-.529.387-.536.387-1.459 0-.929-.387-1.452-.381-.524-1.209-.524-.833 0-1.226.524-.393.523-.393 1.452M4.305 51.436h-.62V49.15H1.173v2.286H.56v-4.9h.613v2.072h2.512v-2.072h.62z\"/\u003e\u003c/g\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M9.433 18.232q0 .756-.256 1.328-.256.565-.756.881-.5.315-1.244.315-.756 0-1.262-.315-.506-.316-.756-.887-.244-.572-.244-1.334 0-.75.244-1.31.25-.565.756-.881.506-.315 1.274-.315.732 0 1.232.315.5.31.756.876.256.565.256 1.327m-3.864 0q0 .923.387 1.459.393.529 1.221.529.839 0 1.22-.529.387-.536.387-1.459 0-.929-.387-1.452-.381-.524-1.208-.524-.834 0-1.227.524-.393.523-.393 1.452M4.353 20.685h-.619v-2.286H1.222v2.286H.608v-4.9h.614v2.072h2.512v-2.072h.619z\"/\u003e\u003c/g\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M35.938 3.078q0 .756-.256 1.328-.256.565-.756.881-.5.315-1.244.315-.756 0-1.262-.315-.506-.316-.756-.887-.244-.572-.244-1.334 0-.75.244-1.309.25-.566.756-.881T33.694.56q.732 0 1.232.316.5.309.756.875.256.565.256 1.327m-3.863 0q0 .923.387 1.459.393.53 1.22.53.84 0 1.221-.53.386-.536.386-1.459 0-.929-.386-1.452-.381-.524-1.209-.524-.833 0-1.226.524-.393.523-.393 1.452M40.245 5.531h-.62V3.245h-2.512v2.286H36.5v-4.9h.613v2.072h2.512V.631h.62z\"/\u003e\u003c/g\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M75.404 25.892q0 .756-.256 1.327-.256.566-.756.881t-1.245.316q-.756 0-1.262-.316-.506-.315-.756-.887-.244-.571-.244-1.333 0-.75.244-1.31.25-.566.756-.881t1.274-.316q.733 0 1.233.316.5.309.756.875t.256 1.328m-3.864 0q0 .922.387 1.458.393.53 1.22.53.84 0 1.221-.53.387-.536.387-1.458 0-.929-.387-1.453-.381-.524-1.209-.524-.833 0-1.226.524t-.393 1.453M79.71 28.344h-.619v-2.286h-2.512v2.286h-.614v-4.899h.614v2.071h2.512v-2.071h.619z\"/\u003e\u003c/g\u003e\u003cpath stroke=\"#ff0d0d\" d=\"M43.474 43.057 38.456 46M46.744 37.217l.002-5.664M33.477 60.262l-.02-5.66M69.861 23.998l-4.957-2.863\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Taste":"Sweet","Therapeutic Uses":"/CLINICAL TRIALS/ ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. The Web site is maintained by the National Library of Medicine (NLM) and the National Institutes of Health (NIH). Each ClinicalTrials.gov record presents summary information about a study protocol and includes the following: Disease or condition; Intervention (for example, the medical product, behavior, or procedure being studied); Title, description, and design of the study; Requirements for participation (eligibility criteria); Locations where the study is being conducted; Contact information for the study locations; and Links to relevant information on other health Web sites, such as NLM's MedlinePlus for patient health information and PubMed for citations and abstracts for scholarly articles in the field of medicine. Glucose is included in the database.","Title":"Glucose","Treatment":"Treatment involves a healthy diet, physical exercise, not using tobacco, and being a normal body weight. Blood pressure control and proper foot care are also important for people with the disease. Type 1 diabetes must be managed with insulin injections. Type 2 diabetes may be treated with medications with or without insulin.","Wikidata":"Q23905964","Wikipedia":"Glucose","XLogP":-2.6,"pH":"pH of 0.5 molar aqueous solution = 5.9 /alpha-glucose/"}